Pregnancies and Neonatal Outcomes in Patients with Sickle Cell Disease (SCD): Still a (High-)Risk Constellation?
complications
genotype–phenotype correlation and patient stratification
patient registries and standardization
pregnancy
sickle cell disease
transfusion
vaso-occlusive (VOC)
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
30 Aug 2021
30 Aug 2021
Historique:
received:
29
07
2021
revised:
26
08
2021
accepted:
27
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
This monocentric study conducted at the University Hospital of Essen aims to describe maternal and fetal/neonatal outcomes in sickle cell disease (SCD) documented between 1996 to 2021 (N = 53), reflecting the largest monocentric analysis carried out in Germany. 46 pregnancies in 22 patients were followed. None of the patients died. In total, 35% (11/31) of pregnancies were preterm. 15 pregnancies in eight patients were conceived on hydroxycarbamide (HC), of which nine had a successful outcome and three were terminated prematurely. There was no difference regarding the rate of spontaneous abortions in patients receiving HC compared to HC-naive patients prior to conception. In patients other than HbS/C disease, pregnancies were complicated by vaso-occlusive crises (VOCs)/acute pain crises (APCs) (96%, 23/24); acute chest syndrome (ACS) (13%, 3/24), transfusion demand (79%, 19/24), urinary tract infections (UTIs) (42%, 10/24) and thromboembolic events (8%, 2/24). In HbS/C patients complications included: VOCs/APCs (43%, 3/7; ACS: 14%, 1/7), transfusion demand (14%, 1/7), and UTIs (14%, 1/7). Independent of preterm deliveries, a significant difference with respect to neonatal growth in favor of neonates from HbS/C mothers was observed. Our data support the results of previous studies, highlighting the high rate of maternal and fetal/neonatal complications in pregnant SCD patients.
Sections du résumé
BACKGROUND
BACKGROUND
This monocentric study conducted at the University Hospital of Essen aims to describe maternal and fetal/neonatal outcomes in sickle cell disease (SCD) documented between 1996 to 2021 (N = 53), reflecting the largest monocentric analysis carried out in Germany.
METHODS/RESULTS
RESULTS
46 pregnancies in 22 patients were followed. None of the patients died. In total, 35% (11/31) of pregnancies were preterm. 15 pregnancies in eight patients were conceived on hydroxycarbamide (HC), of which nine had a successful outcome and three were terminated prematurely. There was no difference regarding the rate of spontaneous abortions in patients receiving HC compared to HC-naive patients prior to conception. In patients other than HbS/C disease, pregnancies were complicated by vaso-occlusive crises (VOCs)/acute pain crises (APCs) (96%, 23/24); acute chest syndrome (ACS) (13%, 3/24), transfusion demand (79%, 19/24), urinary tract infections (UTIs) (42%, 10/24) and thromboembolic events (8%, 2/24). In HbS/C patients complications included: VOCs/APCs (43%, 3/7; ACS: 14%, 1/7), transfusion demand (14%, 1/7), and UTIs (14%, 1/7). Independent of preterm deliveries, a significant difference with respect to neonatal growth in favor of neonates from HbS/C mothers was observed.
CONCLUSION
CONCLUSIONS
Our data support the results of previous studies, highlighting the high rate of maternal and fetal/neonatal complications in pregnant SCD patients.
Identifiants
pubmed: 34575647
pii: jpm11090870
doi: 10.3390/jpm11090870
pmc: PMC8464744
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : German Research Foundation (DFG)
ID : FU356/12-1
Références
South Med J. 2021 Apr;114(4):231-236
pubmed: 33787937
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):446-451
pubmed: 27913514
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):359-366
pubmed: 31808864
Blood. 2013 Aug 8;122(6):1062-71
pubmed: 23723452
Blood. 2014 Dec 18;124(26):3850-7; quiz 4004
pubmed: 25287707
N Engl J Med. 2017 Apr 20;376(16):1561-1573
pubmed: 28423290
Obstet Gynecol Int. 2016;2016:9069054
pubmed: 27403164
Transfusion. 2016 Jan;56(1):107-14
pubmed: 26509333
Blood Adv. 2020 Jan 28;4(2):327-355
pubmed: 31985807
Transfusion. 2015 Dec;55(12):2912-9; quiz 2911
pubmed: 26173835
Rev Bras Hematol Hemoter. 2013;35(1):35-8
pubmed: 23580882
Transfusion. 2009 Mar;49(3):505-12
pubmed: 19040411
Niger Postgrad Med J. 2019 Jan-Mar;26(1):1-7
pubmed: 30860192
Trials. 2020 Apr 20;21(1):347
pubmed: 32312326
Health Qual Life Outcomes. 2006 Aug 31;4:59
pubmed: 16942629
N Engl J Med. 1990 Jun 7;322(23):1617-21
pubmed: 2342522
Transfusion. 2010 Jan;50(1):20-5
pubmed: 19821949
Mediterr J Hematol Infect Dis. 2019 Jul 01;11(1):e2019040
pubmed: 31308916
BJOG. 2016 Apr;123(5):691-8
pubmed: 26667608
Mediterr J Hematol Infect Dis. 2020 Jan 01;12(1):e2020010
pubmed: 31934320
Blood. 2005 Jan 15;105(2):545-7
pubmed: 15454485
Blood. 2015 Nov 19;126(21):2424-35; quiz 2437
pubmed: 26302758
Am J Obstet Gynecol. 2001 May;184(6):1127-30
pubmed: 11349177
Transfusion. 2018 Sep;58(9):2192-2201
pubmed: 29984534
Obstet Gynecol. 1996 Feb;87(2):199-204
pubmed: 8559523
Blood. 2010 Mar 25;115(12):2354-63
pubmed: 19903897
Blood Transfus. 2015 Jan;13(1):72-7
pubmed: 24960646
Blood. 2015 May 21;125(21):3316-25
pubmed: 25800049
Transfus Clin Biol. 2007 Oct;14(4):386-92
pubmed: 18035571